Chlorophyll derivative mediated PDT versus methotrexate: an in vitro study using MCF-7 cells

Area of Science:

• Oncology
• Photodynamic Therapy
• Cancer Therapeutics

Background:

• Breast cancer remains a leading cause of cancer mortality in women globally.
• Photodynamic therapy (PDT) presents a promising alternative to chemotherapy with enhanced tumor selectivity and fewer complications.
• This study evaluates chlorophyll derivative (CHL) as a photosensitizer for breast cancer PDT.

Purpose of the Study:

• To assess the efficacy of photodynamic therapy using a chlorophyll derivative in treating breast cancer.
• To investigate the genetic safety of chlorophyll-mediated PDT compared to conventional chemotherapy.
• To evaluate the potential of CHL as a photosensitizer for breast cancer treatment.

Main Methods:

• MCF-7 breast cancer cell line was targeted using methotrexate (MTX) and light-activated chlorophyll derivative.
• Standard karyotyping and Comet assay were performed on normal human peripheral blood lymphocytes (HPL).
• Genotoxic and mutagenic side effects of both therapeutic modalities were investigated.

Main Results:

• Chlorophyll derivative achieved 50% MCF-7 tumor cell death (LC50) at a concentration 138 times lower than MTX.
• Chlorophyll derivative demonstrated no observable genetic side effects.
• Methotrexate (MTX) treatment resulted in various chromosomal breakages.

Conclusions:

• Light-activated chlorophyll derivative is a more effective agent for breast cancer cell toxicity than MTX.
• Chlorophyll-mediated PDT exhibits superior safety for normal cells and higher efficacy in killing tumor cells.
• The simple extraction method of chlorophyll further supports its potential as a therapeutic agent.